Q-Med AB: Interim report January-June 2010

- Group revenues from sales of goods and royalties amounted to 756 (721) MSEK.

- Earnings per share amounted to 1.40 (5.95) SEK.

- Operating income amounted to 188 (625) MSEK.

- Revenues within the Esthetics product area amounted to 681 (591) MSEK and
operating income was 176 (142) MSEK.

- Net income after tax amounted to 139 (592) MSEK. Income for 2009 was
positively affected by a total of 505 MSEK from a one-time revenue and revenues
from the research collaboration with Oceana Therapeutics.

April - June
- Group revenues from sales of goods and royalties amounted to 392 (382) MSEK
during the second quarter and operating income amounted to 103 (571) MSEK. For
the Esthetics product area operating income amounted to 97 (92) MSEK and for the
Hospital Healthcare product area operating income amounted to 21 (498) MSEK.

- Net income after tax amounted to 80 (550) MSEK during the second quarter.

- On April 27 Q-Med announced that Maria Carell will be succeeding Bengt Ågerup
as CEO of
Q-Med on September 1, 2010.

- Dividend of 149 MSEK was paid to the shareholders during the quarter.


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q‑Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web:
www.q-med.com.


The full report with tables can be downloaded from the following link:


[HUG#1433413]